drugset / Trial / NCT06916702

A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men and Women

NCT06916702

Phase 1 Recruiting 100 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Part A: The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3031185 in healthy male subjects following administration of multiple rising doses. Part B: The main objectives of Part B of this trial are to investigate safety, tolerability, and pharmacokinetics (PK) of BI 3031185 in healthy male subjects and female subjects of non-childbearing potential following oral administration of multiple doses of BI 3031185.

Timeline

Start
2025-04-07
Primary completion
2026-10-07
Completion
2026-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3031185 Unknown Oral
Background Midazolam Small molecule

Indications

No indication recorded.